Adding Libtayo and fianlimab to neoadjuvant chemo improved outcomes over just chemo for patients with triple-negative and HR-positive, HER2-negative breast cancer.
Nearly 20 trials are underway across the country to evaluate the role of vaccines to combat triple-negative breast cancer, including at Georgetown University.
Higher levels of the inflammatory C-reactive protein were discovered in older breast cancer survivors who experienced cognitive issues. The study is one of the first long-term assessments linking chronic inflammation to cognitive decline in breast cancer survivors.